AtaiBeckley names Michael Faerm as finance chief

AtaiBeckley NV (NASDAQ:ATAI, XETRA:9VC) announced that it has appointed Michael Faerm arsenic main fiscal officer, effectual March 9, 2026, arsenic the clinical-stage biotechnology institution continues to beforehand its intelligence wellness attraction pipeline.

According to the company, Faerm brings much than 25 years of acquisition spanning beingness sciences firms, equity probe and concern banking. In the role, helium volition oversee the company’s fiscal strategy, superior markets activities and wide fiscal operations.

Faerm astir precocious served arsenic CFO astatine Viracta Therapeutics. He antecedently held roles including interim CFO astatine Harpoon Therapeutics, which was acquired by Merck, and CFO of Artiva Biotherapeutics. Earlier successful his career, helium served arsenic main concern serviceman astatine Innoviva and held concern improvement and strategical concern roles astatine Forest Laboratories and Regeneron Pharmaceuticals.

His Wall Street acquisition includes elder equity probe roles astatine Credit Suisse and Wells Fargo Securities, covering the pharmaceutical sector, and concern banking astatine Merrill Lynch focused connected healthcare mergers, acquisitions and financings.

AtaiBeckley’s existent CFO Anne Johnson volition modulation to main accounting serviceman upon Faerm’s appointment. The institution said Johnson volition proceed to pb accounting and fiscal operations and enactment intimately with Faerm to enactment continuity.

“We are delighted to invited Mike Faerm to AtaiBeckley arsenic our Chief Financial Officer,” AtaiBeckley CEO and co-founder Srinivas Rao. Rao added that Faerm’s strategical concern inheritance and beingness sciences expertise volition beryllium important arsenic pb campaigner BPL-003 advances toward Phase 3 alongside the company’s broader objective programs.

Rao besides highlighted Johnson’s ongoing role, saying her operational expertise and familiarity with the company’s fiscal systems supply continuity and that the 2 executives signifier a “strong and complementary concern enactment structure.”

Faerm said helium is joining the institution astatine a pivotal time. “With BPL-003 advancing toward Phase 3 and a beardown clinical-stage pipeline supporting the broader strategy, this is simply a compelling clip to assistance signifier the Company’s fiscal and superior markets approach,” helium said.

He added that helium looks guardant to partnering with Johnson and the enactment squad to enactment execution arsenic the institution moves into late-stage development.